GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Shares Outstanding (EOP)

Synthorx (Synthorx) Shares Outstanding (EOP) : 31.87 Mil (As of Sep. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Synthorx Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Synthorx's shares outstanding for the quarter that ended in Sep. 2019 was 31.87 Mil.

Synthorx's quarterly shares outstanding increased from Jun. 2019 (31.71 Mil) to Sep. 2019 (31.87 Mil). It means Synthorx issued new shares from Jun. 2019 to Sep. 2019 .

Synthorx's annual shares outstanding increased from Dec. 2017 (8.67 Mil) to Dec. 2018 (31.39 Mil). It means Synthorx issued new shares from Dec. 2017 to Dec. 2018 .


Synthorx Shares Outstanding (EOP) Historical Data

The historical data trend for Synthorx's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Shares Outstanding (EOP) Chart

Synthorx Annual Data
Trend Dec16 Dec17 Dec18
Shares Outstanding (EOP)
8.67 8.67 31.39

Synthorx Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only 27.42 31.39 31.44 31.71 31.87

Competitive Comparison of Synthorx's Shares Outstanding (EOP)

For the Biotechnology subindustry, Synthorx's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synthorx's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Synthorx's Shares Outstanding (EOP) falls into.



Synthorx Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Synthorx  (NAS:THOR) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Synthorx Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Synthorx's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Synthorx (Synthorx) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037
Executives
Powell Andrew Kenneth William director C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver director, officer: President and CEO 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022